Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
Frontiers in Bioengineering and Biotechnology · 16.02.2023 · 11
DOI: 10.3389/fbioe.2023.1138596 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioengineering and Biotechnology, online erschienen am 16.02.2023. Verfasst von Radwa Ewaisha und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt. Die Arbeit wurde bisher 147-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
CRISPR offers new hope for many patients and promises to transform the way we think of future therapies. Ensuring safety of CRISPR therapeutics is a top priority for clinical translation and specific recommendations have been recently released by the FDA. Rapid progress in the preclinical and clinical development of CRISPR therapeutics leverages years of experience with gene therapy successes and failures. Adverse events due to immunogenicity have been a major setback that has impacted the field of gene therapy. As several in vivo CRISPR clinical trials make progress, the challenge of immunogenicity remains a significant roadblock to the clinical availability and utility of CRISPR therapeutics. In this review, we examine what is currently known about the immunogenicity of CRISPR therapeutics and discuss several considerations to mitigate immunogenicity for the design of safe and clinically translatable CRISPR therapeutics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
- Department of Microbiology and Immunology, School of Pharmacy, Newgiza University, Newgiza, Egypt.
- Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, United States.
Zitieren
APA
Ewaisha, R., & Anderson, K. S. (2023). Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation. Frontiers in Bioengineering and Biotechnology, 11. https://doi.org/10.3389/fbioe.2023.1138596
Vancouver
Ewaisha R, Anderson KS. Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation. Frontiers in Bioengineering and Biotechnology. 2023;11. doi:10.3389/fbioe.2023.1138596
BibTeX
@article{Ewaisha2023,
author = {Ewaisha, Radwa and Anderson, Karen S},
title = {Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation},
journal = {Frontiers in Bioengineering and Biotechnology},
year = {2023},
volume = {11},
doi = {10.3389/fbioe.2023.1138596}
}
EUVIMED